Abstract
Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 58-60 |
| Number of pages | 3 |
| Journal | Infectious Diseases in Clinical Practice |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2013 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- MRSA
- bacteremia
- ceftaroline
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS